Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2023-04-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于2022年度核销坏账及计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Shenzhen Haiwang Bioengineering Co., Ltd. regarding the 2022 annual asset impairment provisions and bad debt write-offs. It details the amounts and reasons for impairment provisions and bad debt write-offs for various asset categories for the fiscal year ending December 31, 2022. The document includes management and independent directors' opinions on the reasonableness and compliance of these provisions. The document is 3637 characters long, which is relatively short and reads like an announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a regulatory announcement about specific accounting actions taken by the company. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-04-27 Chinese
关于为控股子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Haier Bioengineering Co., Ltd. regarding the provision of guarantees for its controlling subsidiary. It details the guarantee amounts, the reasons for the guarantee, the financial status of the subsidiary, and the board's approval. The document is a formal announcement about a financing-related guarantee arrangement rather than a financial report or earnings release. It does not contain financial statements or detailed financial analysis but focuses on the guarantee and related corporate governance matters. This fits the category of Capital/Financing Update (CAP), which covers updates on company financing activities or capital structure changes.
2023-04-27 Chinese
年度关联方资金占用专项审计报告
Regulatory Filings
2023-04-27 Chinese
关于续聘2023年度审计机构的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the reappointment of the external audit firm for the fiscal year 2023. It details the qualifications, independence, and past performance of the audit firm, as well as the approval process by the board and independent directors. It does not contain any financial statements or audit reports themselves, but rather is a notice about the audit firm appointment to be approved by shareholders. The document length is 3457 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it relates specifically to audit matters and the appointment of the audit firm, but is not the audit report itself. However, given the short length and nature as an announcement of audit firm appointment, it aligns more closely with Regulatory Filings (RNS) as it is a regulatory disclosure about audit firm reappointment rather than the audit report or financial statements themselves.
2023-04-27 Chinese
2022年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2022年度监事会工作报告" which translates to "2022 Supervisory Board Work Report". It details the supervisory board's activities, oversight of financial reports, meetings held, and compliance with laws and regulations during the year 2022. It includes references to the review of the 2021 annual report, quarterly reports of 2022, and half-year reports, but it is itself a report on the supervisory board's work rather than the financial reports themselves. The document is 2213 characters long, which is relatively short and more consistent with a management or supervisory report rather than a full annual report or interim report. The content focuses on the supervisory board's oversight and activities, which aligns with a Management Reports (MDA) classification rather than an Annual Report (10-K) or Audit Report (AR). Therefore, the best fit is Management Reports (MDA).
2023-04-27 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board of directors meeting of Shenzhen Haiwang Bioengineering Co., Ltd. It includes voting results on various reports and proposals such as the 2022 annual president's work report, 2022 annual board work report, 2022 financial statements, profit distribution plan, 2023 first quarter report, internal control self-assessment report, remuneration proposals, audit firm reappointment, related party transactions, guarantees, and other corporate governance matters. The document repeatedly states that these matters will be submitted to the shareholders' meeting for approval. The document is not the actual annual report or financial report itself but a formal announcement of board meeting decisions and voting results. It is not a full financial report, earnings release, or audit report. It is not a proxy statement or AGM materials but a board meeting resolution announcement. Therefore, the best fitting category is Board/Management Information (MANG). The document length is 3312 characters, which is relatively short and consistent with a board meeting resolution announcement rather than a full report.
2023-04-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.